146 related articles for article (PubMed ID: 28294690)
1. Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash RP; Rais R; Srinivas NR
Xenobiotica; 2018 Apr; 48(4):422-432. PubMed ID: 28294690
[TBL] [Abstract][Full Text] [Related]
2. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
3. Rabeprazole for the treatment of acid-related disorders.
Marelli S; Pace F
Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):423-35. PubMed ID: 22928894
[TBL] [Abstract][Full Text] [Related]
4. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Baldwin CM; Keam SJ
Drugs; 2009 Jul; 69(10):1373-401. PubMed ID: 19583455
[TBL] [Abstract][Full Text] [Related]
5. Optimal use of proton pump inhibitors for treating acid peptic diseases in primary care.
Tack J; Louis E; Persy V; Urbain D
Acta Gastroenterol Belg; 2013 Dec; 76(4):393-402. PubMed ID: 24592542
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
McLeay SC; Green B; Treem W; Thyssen A; Mannaert E; Kimko H
Clin Pharmacokinet; 2014 Oct; 53(10):943-57. PubMed ID: 25168707
[TBL] [Abstract][Full Text] [Related]
7. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Pallotta S; Pace F; Marelli S
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):509-22. PubMed ID: 19072398
[TBL] [Abstract][Full Text] [Related]
8. Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?
Zhou Q; Yan XF; Pan WS; Zeng S
World J Gastroenterol; 2008 Apr; 14(16):2617-9. PubMed ID: 18442220
[TBL] [Abstract][Full Text] [Related]
9. 25 Years of Proton Pump Inhibitors: A Comprehensive Review.
Strand DS; Kim D; Peura DA
Gut Liver; 2017 Jan; 11(1):27-37. PubMed ID: 27840364
[TBL] [Abstract][Full Text] [Related]
10. [Inadequate response to proton pump inhibitor therapy: causes and patient management tactics].
Evsyutina YV; Trukhmanov AS
Ter Arkh; 2015; 87(2):85-89. PubMed ID: 25864356
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen.
Kimko H; Thyssen A; Mould DR; Mannaert E; Treem WR
J Clin Pharmacol; 2015 May; 55(5):592-600. PubMed ID: 25639255
[TBL] [Abstract][Full Text] [Related]
12. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
[TBL] [Abstract][Full Text] [Related]
13. [Optimal use of proton pump inhibitors in primary care].
Tack J; Louis E; Persy V; Urbain D
Rev Med Liege; 2014 Mar; 69(3):139-45. PubMed ID: 24830213
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors: an update.
Vanderhoff BT; Tahboub RM
Am Fam Physician; 2002 Jul; 66(2):273-80. PubMed ID: 12152963
[TBL] [Abstract][Full Text] [Related]
15. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
16. On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Bruley des Varannes S; Coudsy B; Waechter S; Delemos B; Xiang J; Lococo J; Ducrotté P
Digestion; 2013; 88(1):56-63. PubMed ID: 23880545
[TBL] [Abstract][Full Text] [Related]
17. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Miner P
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
[TBL] [Abstract][Full Text] [Related]
18. Drugs for peptic ulcer disease and GERD.
Treat Guidel Med Lett; 2011 Sep; 9(109):55-60; quiz 2 p following 60. PubMed ID: 21860368
[No Abstract] [Full Text] [Related]
19. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K
Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198
[TBL] [Abstract][Full Text] [Related]
20. A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.
Jain SC;
J Indian Med Assoc; 2009 Feb; 107(2):111-3. PubMed ID: 19585824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
